Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNAL-AD
NCT05509023Phase 2Active, not recruiting
- Sponsor
- Q32 Bio
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bempikibart in atopic dermatitis (AD), sponsored by Q32 Bio. Started Sep 2022; status: active, not recruiting.
02
Drugs
bempikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05509023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509023.